Last updated on January 2020

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis


Brief description of study

This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and B-cell monitoring (BCM).

Detailed Study Description

The screening phase will last up to 24 weeks. In the double-blind treatment phase, participants will undergo at least 120 weeks of study treatment. Study drug (ocrelizumab or placebo) will be administered every 24 weeks. In the FU1 phase, all participants who discontinue prematurely from the double-blind treatment phase will enter the FU1 phase, including participants who receive post-double progression ocrelizumab (PDP OCR) treatment, other immunomodulatory or immunosuppressive treatment(s) for MS, commercial ocrelizumab, or no treatment. The FU1 phase will run in parallel with the double-blind treatment phase until the primary analysis is performed. If the primary analysis is positive, an optional OLE phase is planned for eligible participants who either have remained in the double-blind treatment phase or are on PDP OCR treatment at the time of the primary analysis and, in the opinion of the investigator, could benefit from ocrelizumab treatment. The follow-up 2 (FU2) phase will begin after the primary analysis is performed. The following participants will move into the FU2 phase: participants who are ongoing in the FU1 and not on PDP OCR treatment at the time of primary analysis; participants who are ongoing in the double-blind treatment phase or receiving PDP OCR at the time of the primary analysis and do not enter the OLE phase; participants who complete or withdraw from the OLE phase. At the end of the FU2, all participants will move into B-cell monitoring (BCM) phase until the end of the study. This study will end when all participants who are not being treated with an alternative B-cell depleting therapy have repleted his or her B-cells.

Clinical Study Identifier: NCT04035005

Find a site near you

Start Over

Arcadia Neurology Center

Arcadia, CA United States
  Connect »

SFM Clinical Research, LLC

Boca Raton, FL United States
  Connect »

Vero Neurology

Vero Beach, FL United States
  Connect »

Consultants in Neurology Ltd

Northbrook, IL United States
  Connect »

Michigan Neurology Associates P.C.

Clinton Township, MI United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

Mayo Clinic - PPDS

Rochester, MN United States
  Connect »

University of New Mexico

Albuquerque, NM United States
  Connect »

Dent Neurological Institute

Amherst, NY United States
  Connect »

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

Albert Einstein Medical Center

Philadelphia, PA United States
  Connect »

Premier Neurology

Greer, SC United States
  Connect »

Vanderbilt MS Clinic

Nashville, TN United States
  Connect »

Austin Hospital

Heidelberg, Australia
  Connect »

UZ Antwerpen

Edegem, Belgium
  Connect »

Ottawa Hospital

Ottawa, ON Canada
  Connect »

Jeroen Bosch Ziekenhuis

'S Hertogenbosch, Netherlands
  Connect »

Christchurch Hospital

Christchurch, New Zealand
  Connect »

Dunedin Hospital

Dunedin, New Zealand
  Connect »

Meridian Clinical Research

Norfolk, VA United States
  Connect »

John Hunter Hospital

New Lambton, Australia
  Connect »

Recherche Sepmus, Inc.

Greenfield Park, QC Canada
  Connect »

City Clinical Hospital #12

Nizhny Novgorod, Russian Federation
  Connect »

Nizhniy Novgorod City Hospital #33

Nizhny Novgorod, Russian Federation
  Connect »

Yaroslavl Clinical Hospital #8

Yaroslavl, Russian Federation
  Connect »

City Clinical Hospital #4

Saransk, Russian Federation
  Connect »

Kirov State Medical Academy

Kirov, Russian Federation
  Connect »

Krasnoyarsk State Medical Academy

Krasnoyarsk, Russian Federation
  Connect »

Raigmore Hospital - PPDS

Inverness, United Kingdom
  Connect »

University of Nottingham

Nottingham, United Kingdom
  Connect »

Salford Royal Hospital

Salford, United Kingdom
  Connect »

Royal Hallamshire Hospital

Sheffield, United Kingdom
  Connect »

Morriston Hospital

Swansea, United Kingdom
  Connect »

CHU Tivoli

La Louvière, Belgium
  Connect »